Evidence map›Paper›PMID 28700745›Full record

ArticlePloS one2017

Spatial location of neutralizing and non-neutralizing B cell epitopes on domain 1 of ricin toxin's binding subunit.

Yinghui Rong, Greta Van Slyke, David J Vance, Jennifer Westfall, Dylan Ehrbar, Nicholas J Mantis

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yinghui RongDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.
Greta Van SlykeDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.
David J VanceDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.
Jennifer WestfallDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.
Dylan EhrbarDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.
Nicholas J MantisDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, New York, United States of America.ORCID http://orcid.org/0000-0002-5083-8640
New York State Department of Health · US

Funding

NIAID NIH HHS HHSN272201400021C
6 · The paper itself

Abstract

Ricin toxin's binding subunit (RTB) is a galactose-/N-acetylgalactosamine (Gal/GalNac)-specific lectin that mediates uptake and intracellular trafficking of ricin within mammalian cells. Structurally, RTB consists of two globular domains, each divided into three homologous sub-domains (α, β, γ). In this report, we describe five new murine IgG monoclonal antibodies (mAbs) against RTB: MH3, 8A1, 8B3, LF1, and LC5. The mAbs have similar binding affinities (KD) for ricin holotoxin, but displayed a wide range of in vitro toxin-neutralizing activities. Competition ELISAs indicate that the two most potent toxin-neutralizing mAbs (MH3, 8A1), as well as one of the moderate toxin-neutralizing mAbs (LF1), recognize distinct epitopes near the low affinity Gal recognition domain in RTB subdomain 1α. Evaluated in a mouse model of systemic ricin challenge, all five mAbs afforded some benefit against intoxication, but only MH3 was protective. However, neither MH3 nor 24B11, another well-characterized mAb against RTB subdomain 1α, could passively protect mice against a mucosal (intranasal) ricin challenge. This is in contrast to SylH3, a previously characterized mAb directed against an epitope near RTB's high affinity Gal/GalNac recognition element in sub-domain 2γ, which protected animals against systemic and mucosal ricin exposure. SylH3 was significantly more effective than MH3 and 24B11 at blocking ricin attachment to host cell receptors, suggesting that mucosal immunity to ricin is best imparted by antibodies that target RTB's high affinity Gal/GalNac recognition element in subdomain 2γ, not the low affinity Gal recognition domain in subdomain 1α.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingChlorocebus aethiopsEnzyme-Linked Immunosorbent AssayEpitope MappingEpitopes, B-LymphocyteFemaleMiceMice, Inbred BALB CProtein Structure, SecondaryRicinSurface Plasmon ResonanceVero CellsAntibodies, MonoclonalAntibodies, NeutralizingEpitopes, B-LymphocyteRicin

Identifiers

PMID28700745
PMCPMC5507285
OpenAlexW2734632277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.